The current PE ratio for Biogen stock as of May 3, 2024 is 27.02. This is calculated based on the current EPS of $8.05 and the stock price of $217.51 per share. The P/E ratio has increased by 8% from the past four quarters average of 24.9.
The average historical PE ratio of Biogen for the last ten years is 18.8. The current PE ratio of 27.02 is 44% above the historical average. Over the past ten years, BIIB's PE ratio was at its highest in the Jun 2014 quarter at 34.88, when the stock price was $315.31 and the EPS was $9.04. The lowest value was in the Jun 2020 quarter, when it reached 7.83 with a price of $267.55 and an EPS of $34.19.
Maximum annual increase: 144.28% in 2023
Maximum annual decrease: -47.86% in 2018
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 32.27 | 144.28% |
| 2022 | 13.21 | -42.52% |
| 2021 | 22.98 | 133.3% |
| 2020 | 9.85 | 4.45% |
| 2019 | 9.43 | -32.21% |
| 2018 | 13.91 | -47.86% |
| 2017 | 26.68 | 59.57% |
| 2016 | 16.72 | -16.06% |
| 2015 | 19.92 | -27.11% |
| 2014 | 27.33 | -23.17% |
BIIB's current P/E ratio is above the 3, 5 and 10-year historical averages.
Compared to its peers ABBV and AMGN, BIIB's PE ratio stands lower, however it is higher than JNJ's and GILD's. Biogen's PE ratio is trading below the peer group average of 36.55.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 9.78 | $359.25B |
| GILD Gilead Sciences Inc | 14.27 | $80.7B |
| BIIB Biogen Inc | 27.02 | $31.67B |
| QGEN Qiagen NV | 29.24 | $9.62B |
| AMGN Amgen Inc | 44.22 | $166.99B |
| ABBV AbbVie Inc | 48.6 | $289.23B |
| PFE Pfizer Inc | 73.18 | $157.04B |
| BIO Bio-Rad Laboratories Inc | N/A | $7.98B |
| ILMN Illumina Inc | N/A | $18.79B |
| SGMO Sangamo Therapeutics Inc | N/A | $99.44M |
The price to earnings ratio for BIIB stock as of May 3, 2024, stands at 27.02.
As an average over the last 3 years, BIIB stock has a PE ratio of 21.05.
As an average over the last 5 years, BIIB stock has a PE ratio of 16.51.
The highest quarterly PE ratio in the last ten years has been 34.88 and it was in the Jun 2014 quarter.
The current price to earnings ratio of BIIB is 44% higher than the 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (May 3, 2024), Biogen's stock price is $217.51. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $8.05. Therefore, Biogen's P/E ratio for today is 27.02. PE RATIO(27.02) = STOCK PRICE($217.51) / TTM EPS($8.05)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.